FDA Issues CRLs for Odronextamab in R/R Follicular Lymphoma and R/R DLBCL
OncLive,
The FDA has issued complete response letters (CRLs) to the biologics license application (BLA) seeking the approval of…
Positive Results for Odronextamab in Relapsed/Refractory DLBCL
MedPage Today,
Meeting Coverage > ASH Expert Roundtable: DLBCL But experts aren't sure where it would fit in with currently approved…
Cellular Therapies in Lymphoma Bring Hope, But Optimizing Their Use Remains a Challenge
AJMC,
Recent decades have seen marked improvements in hematological cancer outcomes, with novel therapeutics and sequencing…
FDA Grants Priority Review to Odronextamab in Relapsed/Refractory Follicular Lymphoma or DLBCL
OncLive,
The FDA has granted priority review to the biologics license application (BLA) seeking the approval of odronextamab (REGN1979…